フルテキストファイル
著者
Harada Tasuku Department of Obstetrics and Gynecology, School of Medicine, Tottori University Faculty of Medicine 鳥取大学研究者総覧 KAKEN研究者をさがす
Ohta Ikuko Department of Obstetrics and Gynecology, Kurashiki Heisei Hospital
Endo Yusuke Advanced Medicine, Innovation and Clinical Research Center, Tottori University Hospital 鳥取大学研究者総覧
Sunada Hiroshi Advanced Medicine, Innovation and Clinical Research Center, Tottori University Hospital 鳥取大学研究者総覧
Noma Hisashi Department of Data Science, The Institute of Statistical Mathematics
Taniguchi Fuminori Department of Obstetrics and Gynecology, School of Medicine, Tottori University Faculty of Medicine 鳥取大学研究者総覧 KAKEN研究者をさがす
キーワード
estrogen receptor
endometriosis
selective estrogen receptor modulator
pelvic pain
open clinical trial
抄録
[Background]SR-16234 is a selective estrogen receptor modulator (SERM) structurally different from approved SERM and has been reported to have estrogen receptor (ER) α antagonistic activity and strong affinity with a weak partial agonistic activity to ERβ receptor. SR-16234 showed strong inhibitory effects on transplanted endometrial cysts in the endometriosis model of rat and mouse. In this clinical trial, efficacy and safety of SR-16234 have been evaluated in endometriosis patients.
[Methods]This trial was an open-label single arm clinical trial. Ten patients with dysmenorrhea and pelvic pain associated with endometriosis and adenomyosis were enrolled in this trial, and received 40 mg of SR-16234 once daily for 12 weeks. The primary endpoint was the visual analogue scale (VAS) of pelvic pain. The secondary endpoints included dysmenorrhea score, pelvic pain score, objective observations (stiffness of Douglas’ pouch, limitation of uterine movement, size of ovarian chocolate cysts, thickness of endometrium, and serum CA125 concentration) and safety.
[Results]After oral administration of SR-16234 40 mg for 12 weeks, there were statistically significant decreases in pelvic pain VAS, total pelvic pain score, total dysmenorrhea score, stiffness of Douglas’ pouch, limitation of uterine movement compared with the baseline values.
[Conclusion]The present trial suggested that a selective estrogen receptor modulator could be used for treatment of pain associated with endometriosis for the first time.
出版者
Tottori University Faculty of Medicine
資料タイプ
学術雑誌論文
ISSN・ISBN
1346-8049
書誌ID
AA00892882
掲載誌名
Yonago Acta Medica
最新掲載誌名
Yonago Acta Medica
60
4
開始ページ
227
終了ページ
223
発行日
2018-02-05
著者版フラグ
出版社版
掲載情報
Yonago Acta Medica. 2017, 60(4), 227-223
部局名
医学部・医学系研究科・医学部附属病院
言語
英語